Eyebright Medical Technology Co., Ltd (SHA: 688050), a Beijing-based company specializing in ophthalmic medical devices, is poised to issue 8,420,079 Global Depository Receipts (GRDs) on the SIX Exchange, pending approval from the Swiss bourse and regulatory filing in China. The listing is anticipated to generate a take-home amount of RMB 1.4 billion (USD 192 million) for the company, which plans to allocate the funds to various strategic initiatives.
Funds Allocation for Strategic Growth
The proceeds from the listing are earmarked for several key projects, including M&A initiatives, Phase II production for an ophthalmic product, development of an ophthalmic medical device, expansion of the company’s pharmaceutical contact lens project, product production in Germany, and a channel construction project. These investments are set to bolster Eyebright Medtech’s market presence and enhance its product offerings.
Company Background and Global Reach
Founded in 2010, Eyebright Medtech is dedicated to the research and development, manufacturing, sales, and service of ophthalmic medical devices. The company’s portfolio encompasses solutions for surgical treatment, myopia prevention and control, and vision care. With a business presence spanning over 30 countries, including Germany, France, Italy, the UK, Switzerland, Colombia, South Africa, South Korea, Thailand, Australia, and more, Eyebright Medtech has established a significant global footprint in the ophthalmic medical device sector.-Fineline Info & Tech
